Cytokines and Myocardial Dysfunction: State of the Art

Journal of Cardiac Failure

Volumn 14, Issue 1, 2008, Pages 61-74

  El Menyar, Ayman A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

Cytokine; heart failure; interleukin; myocardial dysfunction proinflammatory; tumor necrosis factor

Indexed keywords

ALPHA CHEMOKINE; AMIODARONE; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CARVEDILOL; CHEMOKINE; CYTOKINE; ENDOTHELIN; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; METOPROLOL; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OUABAGENIN; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHOLIPID; SPHINGOLIPID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; UNINDEXED DRUG;

CARDIAC RESYNCHRONIZATION THERAPY; CONGESTIVE CARDIOMYOPATHY; CRITICAL ILLNESS; CYTOKINE PRODUCTION; DISEASE COURSE; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART VENTRICLE REMODELING; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; INFLAMMATION; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW;

BIOLOGICAL MARKERS; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; CYTOKINES; FEMALE; HEART FAILURE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38549102037     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2007.09.006     Document Type: Review

References (154)

1. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76 (1994) 301-314
2. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 14 (1996) 397-440
3. Mann D.L. Recent insights into the role of tumor necrosis factor in the failing heart. Heart Fail Rev 6 (2001) 71-80
4. Torre-Amione G., Kapadia S., Lee J., et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93 (1996) 704-711
5. Mehra V.C., Ramgolam V.S., and Bender J.R. Cytokines and cardiovascular disease. J Leukoc Biol 78 (2005) 805-818
6. Prabhu S. Cytokine-modulation of cardiac function. Circ Res 95 (2004) 1140-1153
7. Anker S.D., and von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 90 (2004) 464-470
8. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol 95 (2005) 3C-8C
9. Mann D.L. Inflammatory mediators and the failing heart. Past, present, and the foreseeable future. Circ Res 91 (2002) 988-998
10. Huber-Lang M.S., Younkin E.M., Sarma J.V., et al. Complement-induced impairment of innate immunity during sepsis. J Immunol 169 (2002) 3223
11. Riedemann N.C., Guo R.F., Neff T.A., et al. Increased C5a receptor expression in sepsis. J Clin Invest 110 (2002) 101
12. Piagnerelli M., Boudjeltia K.Z., Vanhaeverbeek M., and Vincent J.L. Red blood cell rheology in sepsis. Intensive Care Med 29 (2003) 1052
13. Testa M., Yeh M., Lee P., et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 28 (1996) 964-971
14. Rauchhaus M., Doehner W., Francis D.P., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102 (2000) 3060-3067
15. Aukrust P., Gullestad L., Ueland T., Dama J.K., and Yndestad A. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med 37 (2005) 74-85
16. Vasan R.S., Sullivan L.M., Roubenoff R., et al. Inflammatory markers and risk of heart failure in elderly subjects without a prior myocardial infarction: the Framingham Study. Circulation 107 (2003) 1486-1491
17. Joulin O., Petillot P., Labalette M., et al. Cytokine profile of human septic shock serum inducing cardiomyocyte contractile dysfunction. Physiol Res 56 (2007) 291-297
18. Adamy C., Le Corvoisier P., Candiani G., et al. Tumor necrosis factor alpha and glutathione interplay in chronic heart failure. Arch Mal Coeur Vaiss 98 (2005) 906-912
19. Amadou A., Nawrocki A., Best-Belpomme M., et al. Arachidonic acid mediates dual effect of TNF-alpha on Ca2+ transients and contraction of adult rat cardiomyocytes. Am J Physiol Cell Physiol 282 (2002) C1339-C1347
20. Cailleret M., Amadou A., Andrieu-Abadie N., et al. N-acetylcysteine prevents the deleterious effect of tumor necrosis factor-(alpha) on calcium transients and contraction in adult rat cardiomyocytes. Circulation 109 (2004) 406-411
21. Pathan N., Hemingway C.A., Alizadeh A.A., et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet 363 (2004) 203-209
22. Torre-Amione G., Kapadia S., Benedict C., et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27 (1996) 1201-1206
23. Bozkurt B., Kribbs S., Clubb Jr. F.J., et al. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97 (1998) 1382-1391
24. Eriksson S.V., Kjekshus J., Eneroth P., and Swedberg K. Neopterin, tumor necrosis factor, C-reactive and prostaglandin E2 in patients with severe congestive heart failure treated with enalapril. Circulation 96 suppl I (2000) I-322. [abstract]
25. Gullestad L., Aukrust P., Ueland T., et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 34 (1999) 2061-2067
26. Gurlek A., Kilickap M., Dincer I., Dandachi R., Tutkak H., and Oral D. Effect of losartan on circulating TNF-α levels and left ventricular systolic performance in patients with heart failure. J Cardiovasc Risk 8 (2001) 279-282
27. Tsutamoto T., Wada A., Matsumoto T., et al. Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J Am Coll Cardiol 37 (2001) 2086-2092
28. Thaik C.M., Calderone A., Takahashi N., and Colucci W.S. Interleukin-1b modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 96 (1995) 1093-1099
29. Kubota T., McTiernan C.F., Frye C.S., et al. Dilated cardiomyopathy in transgenic mice with cardiac specific overexpression of tumor necrosis factor-alpha. Circ Res 81 (1997) 627-635
30. Seta Y., Shan K., Bozkurt B., Oral H., and Mann D.L. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 2 (1996) 243-249
31. Eddy L.J., Goeddel D.V., and Wong G.H. Tumor necrosis factor-alpha pretreatment is protective in a rat model of myocardial ischemia-reperfusion injury. Biochem Biophys Res Commun 184 (1992) 1056-1059
32. Wong G.H., and Goeddel D.V. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 242 (1988) 941-944
33. Nakano M., Knowlton A.A., Yokoyama T., et al. Tumor necrosis factor-induced expression of heat shock protein 72 in adult feline cardiac myocytes. Am J Physiol 270 (1996) H1231-H1239
34. Plumier J.C., Ross B.M., Currie R.W., et al. Transgenic mice expressing the human heat shock protein 70 have improved post-ischemic myocardial recovery. J Clin Invest 95 (1995) 1854-1860
35. Deswal A., Petersen N.J., Feldman A.M., et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103 (2001) 2055-2059
36. Torre-Amione G., Kapadia S., Lee J., Bies R.D., Lebovitz R., and Mann D.L. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 92 (1995) 1487-1493
37. Torre-Amione G., Bozkurt B., Deswal A., and Mann D.L. An overview of tumour necrosis factor a and the failing human heart. Curr Opin Cardiol 14 (1999) 206-210
38. Feldman A.M., Combes A., Wagner D., et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 35 (2000) 537-544
39. Dinarello C.A., Cannon J.G., Wolff S.M., et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 163 (1986) 1433-1450
40. Yokoyama T., Nakano M., Bednarczyk J.L., McIntyre B.W., Entman M., and Mann D.L. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 95 (1997) 1247-1252
41. Nakano M., Knowlton A.A., Dibbs Z., and Mann D.L. Tumor necrosis factor-alpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation 97 (1998) 1392-1400
42. Bryant D., Becker L., Richardson J., et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 97 (1998) 1375-1381
43. Nagueh S.F., Stetson S.J., Lakkis N.M., et al. Decreased expression of tumor necrosis factor-alpha and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy. Circulation 103 (2001) 1844-1850
44. Kapadia S.R., Yakoob K., Nader S., Thomas J.D., Mann D.L., and Griffin B.P. Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. J Am Coll Cardiol 36 (2000) 208-212
45. Sacher R.A., and for the IVIG Advisory Panel. Intravenous immunoglobulin consensus statement. J Allergy Clin Immunol 108 suppl (2001) S139-S146
46. Yokoyama T., Nakano M., Bednarczyk J.L., et al. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 95 (1997) 1247-1252
47. Krown K.A., Page M.T., Nguyen C., et al. Tumor necrosis factor alpha induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 98 (1996) 2854-2865
48. Murray D.R., and Freeman G.L. Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs. Circ Res 78 (1996) 154-160
49. Gulick T., Chung M., Pieper S.J., et al. Interleukin1 and tumor necrosis factor inhibit cardiac myocytes beta-adrenergic responsiveness. Proc Natl Acad Sci U S A 86 (1989) 6753-6757
50. Panas D., Khadour F.H., Szabo C., and Schulz R. Proinflammatory cytokines depress cardiac efficiency by a nitric oxide-dependent mechanism. Am J Physiol 275 (1998) H1016-H1023
51. Finkel M.S., Oddis C.V., Jacob T.D., Watkins S.C., Hattler B.G., and Simmons R.L. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257 (1992) 387-389
52. Dibbs Z., Thornby J., White B.G., et al. Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol 33 (1999) 1935-1942
53. Kapadia S., Torre-Amione G., and Mann D.L. Pitfalls in measuring cytokines. Ann Intern Med 121 (1994) 149-150
54. Kumar A., Haery C., and Parrillo J.E. Myocardial dysfunction in septic shock. Crit Care Clin 16 (2000) 251-287
55. Parrillo J.E., Burch C., Shelhamer J.H., Parker M.M., Natanson C., and Schuette W. A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 76 (1985) 1539-1553
56. Kumar A., Wood K., and Parrillo J.E. Circulating substances and energy metabolism in septic shock. Crit Care Med 31 (2003) 632-633
57. Cain B.S., Meldrum D.R., Dinarello C.A., et al. Tumor necrosis factor-α and interleukin-1β synergistically depress human myocardial function. Crit Care Med 27 (1999) 1309-1318
58. El-Menyar A.A. The resuscitation outcome: revisit the story of the stony heart. Chest 128 (2005) 2835-2846
59. El-Menyar A. Pathophysiology and hemodynamic of postresuscitation syndrome. Saudi Med J 27 (2006) 441-445
60. Sharma H.S., and Das D.K. Role of cytokines in myocardial ischemia and reperfusion. Mediators Inflamm 6 (1997) 175-183
61. Niemann J.T., Garner D., and Lewis R.J. Tumor necrosis factor-alpha is associated with early postresuscitation myocardial dysfunction. Crit Care Med 32 (2004) 1753-1758
62. Ferrari R., Bachetti T., Confortini R., et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 92 (1995) 1479-1486
63. Aukrust P., Ueland T., Lien E., et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 83 (1999) 376-382
64. Chung E.S., Packer M., Lo K.H., et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
65. Meldrum D.R., Dinarello C.A., Shames B.D., et al. Ischemic preconditioning decreases postischemic myocardial tumor necrosis factor-alpha production: potential ultimate effector mechanism of preconditioning. Circulation 98 suppl II (1998) II-214-18
66. Anker S.D., Ponikowski P.P., Clark A.L., et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 20 (1999) 683-693
67. Van Deventer S.J.H., Buller H.R., Ten Cate J.W., et al. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 76 (1990) 2520-2526
68. Ng S.B., Tan Y.N., and Guy G.R. Differential induction of the interleukin-6 gene by tumor necrosis factor and interleukin-1. J Biol Chem 269 (1994) 19021-19027
69. Sanceau J., Kaisho T., Hirano T., and Wietzerbin J. Triggering of the human interleukin-6 gene by interferon-g and tumor necrosis factor-α in monocyte cells involves cooperation between interferon regulatory factor-1, NFkB, and SP1 transcription factors. J Biol Chem 270 (1995) 27920-27931
70. Baumann H., and Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med 7 (1990) 147-159
71. Heinrich P.C., Castell J.V., and Andus T. Interleukin-6 and the acute phase response. Biochem J 265 (1990) 621-636
72. Tsutamoto T., Hisanaga T., Wada A., et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 31 (1998) 391-398
73. Mohler E.R., Sorensen L.C., Ghali J.K., et al. Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial: Prospective Randomized Amlodipine Survival Evaluation. J Am Coll Cardiol 30 (1997) 35-41
74. Sugishita K., Kinugawa K., Shimizu T., et al. Cellular basis for the acute inhibitory effects of IL-6 and TNF on excitation-contraction coupling. J Mol Cell Cardiol 31 (1999) 1457-1467
75. Maeda K., Tsutamoto T., Wada A., et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 36 (2000) 1587
76. Adrie C., Adib-Conquy M., Laurent I., et al. Successful cardiopulmonary resuscitation after cardiac arrest as a "sepsis-like" syndrome. Circulation 106 (2002) 562-568
77. Kinugawa K., Takahashi T., Kohmoto O., et al. Nitric oxide-mediated effects of interleukin-6 on [Ca2+]i and cell contraction in cultured chick ventricular myocytes. Circ Res 75 (1994) 285-295
78. Geppert A., Steiner A., Zorn G., et al. Multiorgan failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med 30 (2002) 1987-1994
79. Rao K.M. Molecular mechanisms regulating iNOS expression in various cell types. J Toxicol Environ Health B Crit Rev 3 (2000) 27-58
80. Finkel M.S., Oddis C.V., Jacob T.D., et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257 (1992) 387-389
81. Bolger A.P., Sharma R., von Haehling S., et al. Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure. Am J Cardiol 90 (2002) 384-389
82. Nishio R., Matsumori A., Shioi T., Ishida H., and Sasayama S. Treatment of experimental viral myocarditis with interleukin-10. Circulation 100 (1999) 1102-1108
83. Gullestad L., Aass H., Fjeld J.G., et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 103 (2001) 220-225
84. Kaur K., Sharma A.K., and Singal P.K. Significance of changes in TNF-alpha and IL-10 levels in the progression of heart failure subsequent to myocardial infarction. Am J Physiol Heart Circ Physiol 291 (2006) H106-H113
85. Nishii M., Inomata T., Takehana H., et al. Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis. J Am Coll Cardiol 44 (2004) 1292-1297
86. Damås J.K., Eiken H.G., Oie E., et al. Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res 47 (2000) 778-787
87. Aukrust P., Ueland T., Muller F., et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 97 (1998) 1136-1143
88. Damas J.K., Gullestad L., Ueland T., et al. CXC-chemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes. Cardiovasc Res 45 (2000) 428-436
89. Damas J.K., Gullestad L., Aass H., et al. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure-modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol 38 (2001) 187-193
90. Vadlamani L., and Abraham W.T. Insights into pathogenesis and treatment of cytokines in cardiomyopathy. Curr Cardiol Rep 2 (2000) 120-128
91. Wei C.M., Lerman A., Rodeheffer R.J., et al. Endothelin in human congestive heart failure. Circulation 89 (1994) 1580-1586
92. Galtius-Jensen S., Wroblewski H., Emmeluth C., et al. Plasma endothelin in congestive heart failure: a predictor of cardiac death?. J Card Fail 2 (1996) 71-76
93. McMurray J.J., Ray S.G., Abdullah I., et al. Plasma endothelin in chronic heart failure. Circulation 85 (1992) 1374-1379
94. Anand I.S., Latini R., Florea V.G., et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112 (2005) 1428
95. Alonso-Martínez J.L., Llorente-Diez B., Echegaray-Agara M., Olaz-Preciado F., Urbieta-Echezarreta M., and González-Arencibia C. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 4 (2002) 331-336
96. Birks E.J., Owen V.J., Burton P.B., et al. Tumor necrosis factor-alpha is expressed in donor heart and predicts right ventricular failure after human heart transplantation. Circulation 102 (2000) 326-331
97. Tatli E., and Kurum T. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy. Can J Cardiol 21 (2005) 344-348
98. Gullestad L., Ueland T., Brunsvig A., et al. Effect of metoprolol on cytokine levels in chronic heart failure-a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). Am Heart J 141 (2001) 418-421
99. Ohtsuka T., Hamada M., Saeki H., et al. Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 89 (2002) 996-999
100. Lappegard K.T., and Bjornstad H. Anti-inflammatory effect of cardiac resynchronization therapy. Pacing Clin Electrophysiol 29 (2006) 753-758
101. Mann D.L. Cytokines as mediators of disease progression in the failing heart. In: Hosenpud J.D., and Greenberg B.H. (Eds). Congestive heart failure (1999), Lippincott Williams & Wilkins, Philadelphia 212-232
102. Mann D.L. Targeted anticytokine therapy and the failing heart. Am J Cardiol 95 suppl (2005) 9C-16C
103. Yoshimura T., Kurita C., Nagoa T., et al. Inhibition of tumor necrosis factor-alpha and interleukin-1 beta production by beta-adrenoceptor agonists from lipopolysaccharide-stimulated human peripheral blood mononuclear cells. Pharmacology 54 (1997) 144-152
104. Szabo C., Hasko G., Zingarelli B., et al. Isoproterenol regulates tumor necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxemia. Immunology 90 (1997) 95-100
105. Matsumori A., Shioi T., Yamada T., Matsui S., and Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 89 (1994) 955-958
106. Sliwa K., Skudicky D., Candy G., Wisenbaugh T., and Sareli P. Randomized investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 351 (1998) 1091-1093
107. Zabel P., Wolter D.T., Schonharting M.M., and Schade U.F. Oxpentifylline in endotoxaemia. Lancet 23 (1989) 1474-1477
108. Bergman M.R., and Holycross B.J. Pharmacological modulation of myocardial tumor necrosis factor alpha production by phosphodiesterase inhibitors. J Pharmacol Exp Ther 279 (1996) 247-254
109. Feldman A.M., McNamara D.M., and Wagner D.R. AMPD1 gene mutation in congestive heart failure: new insights into the pathobiology of disease progression. Circulation 99 (1998) 1397-1399
110. Matsumori A., Ono K., Nishio R., Nose Y., and Sasayama S. Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells. A possible mechanism for its effect in heart failure. Circulation 96 (1997) 1386-1389
111. Matsumori A., Ono K., Nishio R., et al. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. Circulation 96 (1997) 1501-1506
112. Ammann P., Rizzoli R., and Bonjour J.P. Transgenic mice expressing soluble tumor necrosis factor are protected against bone loss caused by estrogen deficiency. J Clin Invest 99 (1997) 1699-1703
113. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101 (1998) 2711-2719
114. Laufs U., La Fata V., Plutzky J., et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
115. Node K., Fujita M., Kitakaze M., et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
116. Tousoulis D., Antoniades C., Bosinakou E., et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 178 (2005) 359-363
117. Oi S., Haneda T., Osaki J., et al. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 376 (1999) 139-148
118. Bellosta S., Via D., Canavesi M., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18 (1998) 1671-1678
119. Tousoulis D., Antoniades C., Bosinakou E., et al. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 91 (2005) 27-31
120. Strey C.H., Young J.M., Molyneux S.L., et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis 179 (2005) 201-206
121. Weinblatt M.E., Kremer J.M., Bankhurst A.D., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340 (1999) 253-259
122. Mease P.J., Goffe B.S., Metz J., et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356 (2000) 385-390
123. Kapadia S., Torre-Amione G., Yokoyama T., et al. Soluble tumor necrosis factor binding proteins modulate the negative inotropic effects of TNF in vitro. Am J Physiol 37 (1995) H517-H525
124. Deswal A., Bozkurt B., Seta Y., et al. A phase I trial of tumor necrosis factor receptor (p75) fusion protein (TNFR:Fc) in patients with advanced heart failure. Circulation 99 (1999) 3224-3226
125. Bozkurt B., Torre-Amione G., Warren M.S., et al. Results of targeted ant-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 103 (2001) 1044-1047
126. Mann D.L., McMurray J.J., Packer M., et al. Targeted Anticytokine Therapy in Patients With Chronic Heart Failure Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
127. Anker S.D., and Coats A.J. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 86 (2002) 123
128. US Food and Drug Administration. Update on the TNF-a blocking agents. Available at: www.fda.gov/ohrms/dockets/ac/03/briefing/3930b1.htm. Accessed March 3, 2003.
129. Kwon H.J., Cote T.R., Cuffe M.S., Kramer J.M., and Braun M.M. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138 (2003) 807-811
130. Sarzi-Puttini P., Atzeni F., Doria A., Iaccarino L., and Turie M. Tumor necrosis factor-alpha, biologic agents and cardiovascular risk. Lupus 14 (2005) 780-784
131. Sugamori T., Ishibashi Y., Shimada T., et al. Increased nitric oxide in proportion to the severity of heart failure in patients with dilated cardiomyopathy: close correlation of tumor necrosis factor-alpha with systemic and local production of nitric oxide. Circ J 66 (2002) 627-632
132. Kurrelmeyer K.M., Michael L.H., Baumgarten G., et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci U S A 97 (2000) 5456-5461
133. Packer M. Role of the sympathetic nervous system in chronic heart failure: a historical and philosophical perspective. Circulation 82 Suppl (1990) I1-I6
134. Sarzi-Puttini P., Atzeni F., Shoenfeld Y., and Ferraccioli G. TNF-a rheumatoid arthritis and heart failure: a rheumatological dilemma. Autoimmun Rev 4 (2005) 153-161
135. Khanna D., McMahon M., and Furst D.E. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?. Arthritis Rheum 50 (2004) 1040-1050
136. von Haehling S., Jankowska E.A., and Anker S.D. Tumour necrosis factor-alpha and the failing heart-pathophysiology and therapeutic implications. Basic Res Cardiol 99 (2004) 18-28
137. von Haehling S., and Anker S.D. Future prospects of anticytokine therapy in chronic heart failure. Expert Opin Investig Drugs 14 (2005) 163-176
138. Suffredini A.F., Reda D., Banks S.M., Tropea M., Agosti J.M., and Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 155 (1995) 5038-5045
139. Kubota T., McNamara D.M., Wang J.J., et al. Effects of tumour necrosis factor gene polymorphisms on patients with congestive heart failure. VEST investigators for TNF-genotype-analysis. Vesnarinone Survival Trial. Circulation 97 (1998) 2499-2501
140. Kadokami T., McTiernan C.F., Frye C.S., et al. Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. J Clin Invest 106 (2000) 589-597
141. Staudt A., Landsberger M., Staudt Y., and Felix S.B. Cytokines-Causes, players, or by standers in heart failure. Herz 27 (2002) 691-698
142. Feldman A.M., and McTiernan C. Is there any future for tumor necrosis factor antagonists in chronic heart failure?. Am J Cardiovasc Drugs 4 (2004) 11-19
143. Clark M.A., Plank L.D., Connolly A.B., et al. Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis: a randomized, clinical trial. Crit Care Med 26 (1998) 1650-1659
144. Scallon B.J., Moore M.A., Trinh H., et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7 (1995) 251-259
145. Opal S.M., Cross A.S., Kelly N.M., et al. Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. J Infect Dis 161 (1990) 1148-1152
146. Kojouharoff G., Hans W., Obermeier F., et al. Neutralization of tumor necrosis factor (TNF), but not of IL-1, reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 107 (1997) 353-358
147. McNamara D.M., Holubkov R., Starling R.C., et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 103 (2001) 2254-2259
148. Muller J., Wallukat G., Dandel M., et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 101 (2000) 385-391
149. Bolton A.E. Biologic effects and basic science of a novel immune-modulation therapy. Am J Cardiol 95 suppl (2005) 24C-29C
150. Torre-Amione G., Bourge R.C., Colucci W.S., et al. ACCLAIM Investigators. A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: the ACCLAIM trial rationale and design. Can J Cardiol 23 (2007) 369-376
151. ACCLAIM: Immune-modulation therapy fails to meet primary end point in CHF study. Available at: http://www.theheart.org/article/718941.do and http://clinicaltrials.gov/ct/show/NCT00111969?order=2. Accessed August 29, 2007.
152. Khanna D., McMahon M., and Furst D.E. Anti-tumor necrosis factor: therapy and heart failure. What have we learned and where do we go from here?. Arthritis Rheum 50 (2004) 1040-1050
153. Kadokami T., Frye C., Lemster B., et al. Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model. Circulation 104 (2001) 1094-1097
154. Kubota T., Bounoutas G.S., Miyagishima M., et al. Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation 101 (2000) 2518-2525